HLA-A and hepatocellular carcinoma: In both assays, the two types of effector cells were the HLA-A*02:01-restricted GPC3144–152 peptide-specific CTL clone, which was established from peripheral blood mononuclear cells (PBMCs) of an HCC patient who had received the GPC3144–152 peptide vaccine [16], and the HLA-A*02:01-restricted CMV495–503 peptide-specific CTL clone, which was established from PBMCs of a healthy volunteer.